Abstract
Annexin A9 (ANXA9), a member of the annexin family, has been implicated in colorectal cancer (CRC) carcinogenesis, yet its specific role in invasion and metastasis remains poorly defined. This study investigates the clinical significance and molecular mechanisms of ANXA9 in CRC. Using immunohistochemistry (IHC) and Western blotting, we found that ANXA9 is significantly overexpressed in CRC tissues compared to adjacent mucosa, correlating with invasion depth and lymphatic metastasis. Functional assays in HCT116 cells revealed that ANXA9 knockdown inhibits cell activity, migration, and invasion by modulating the ADAM17/MMP-9 axis and E-cadherin expression. These findings suggest ANXA9 is a novel prognostic marker and a potential therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) is a major global health burden, often characterized by late-stage diagnosis and high metastatic potential. The Annexin family of calcium-dependent phospholipid-binding proteins is known to influence various oncogenic processes. This study focuses on Annexin A9 (ANXA9), aiming to clarify its prognostic value and its role in the "migratory machinery" that facilitates CRC spread.
Methods
The study utilized a cohort of 105 CRC patients from The Third Hospital of Hebei Medical University. ANXA9 protein levels were quantified in CRC tissues and adjacent healthy mucosa via IHC and Western blotting. Survival outcomes were analyzed using Kaplan-Meier curves and Cox proportional hazards models. In vitro experiments were conducted using the HCT116 cell line, where ANXA9 was silenced using siRNA. Functional impacts were assessed through MTT, wound healing, and Transwell assays, while molecular changes were tracked via qPCR and Western blotting for markers like ADAM17, MMP-9, TIMP-1, and E-cadherin.
Results
ANXA9 Overexpression in CRC Tissues
Analysis of clinical samples revealed a stark contrast in ANXA9 expression between malignant and healthy tissues. IHC results showed a positivity rate of 76.19% in CRC tissues versus 16.19% in adjacent mucosa. This was corroborated by Western blot analysis, which demonstrated significantly higher relative expression of ANXA9 protein in CRC samples compared to control tissues.
Prognostic Significance
High ANXA9 expression was strongly associated with advanced clinicopathological features, including deeper tumor infiltration and increased lymphatic metastasis. Most notably, Kaplan-Meier analysis indicated that patients with ANXA9-positive tumors had significantly poorer overall survival compared to those with ANXA9-negative tumors ($P=0.005$). Multivariate analysis confirmed ANXA9 as an independent risk factor for survival.
Molecular Mechanisms of Invasion and Metastasis
Silencing ANXA9 in HCT116 cells significantly reduced their proliferative, migratory, and invasive capacities. At the molecular level, ANXA9 knockdown led to the downregulation of pro-metastatic enzymes ADAM17 and MMP-9, while upregulating their inhibitor TIMP-1. Furthermore, the loss of ANXA9 increased the expression of E-cadherin, suggesting that ANXA9 promotes metastasis by facilitating Epithelial-Mesenchymal Transition (EMT) and extracellular matrix degradation.
Discussion
This study identifies ANXA9 as a critical driver of CRC progression. By regulating the ADAM17/MMP-9 axis and suppressing E-cadherin, ANXA9 enhances the invasive potential of CRC cells. While the exact signaling intermediates remain to be fully mapped, the strong correlation between ANXA9 levels and poor patient outcomes highlights its potential as a robust prognostic biomarker. Future research using in vivo models will be essential to further validate these findings and explore ANXA9 as a therapeutic target.
Summary updated